Keywords: Theravance, Vibatic, USA, FDA advisory panel, Nosocomial pneumonia

Mixed FDA panel vote for Theravance's Vibativ for nosocomial pneumonia

Article | 03 December 2012

Print This

US drug developer Theravance (Nasdaq: THRX) saw its shares rise more than 5% $22.48 by close of trading on Friday, after the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in